Advertisement

SignalChem, Merck to evaluate SLC-391 + Keytruda in phase II study of advanced NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

SignalChem Lifesciences, and a subsidiary of Merck, are evaluating the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with Keytruda (pembrolizumab) in patients with advanced non-small cell lung cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

The day before health economist Jay Bhattacharya stepped into his new role as NIH director, he sent a document to his employees outlining his top five priorities for the department, which included “reproducibility” and “transparency,” two themes he discussed at his confirmation hearings (The Cancer Letter, March 7, 2025).
Advertisement
Advertisement